[Systemic treatment of brain metastases from breast cancer: cytotoxic chemotherapy and targeted therapies].

Bull Cancer 2013 Jan;100(1):7-14

Centre Léon-Bérard, oncologie médicale, 69008 Lyon, France.

Prevalence of brain metastases is increasing in breast cancer. Brain metastases represent a poor-prognosis disease for which local treatments continue to play a major role. In spite of the presence of a physiological blood-brain barrier limiting their activity, some systemic treatments may display a significant antitumor activity at the central nervous system level. In HER2-positive metastatic breast cancer with brain metastases not previously treated with whole brain radiotherapy, capecitabine and lapatinib combination obtains a volumetric reponse in two thirds of patients (LANDSCAPE study). If confirmed, these results could modify in selected patients the layout of therapeutic strategies. Promoting novel targeted approaches and innovative therapeutic combinations is a critical need to improve survival of breast cancer patients with brain metastases.

Download full-text PDF

Source
http://dx.doi.org/10.1684/bdc.2012.1676DOI Listing
January 2013
9 Reads

Publication Analysis

Top Keywords

brain metastases
20
breast cancer
16
cancer brain
8
brain
6
metastases
5
brain radiotherapy
4
treated brain
4
metastatic breast
4
radiotherapy capecitabine
4
metastases treated
4
volumetric reponse
4
combination obtains
4
her2-positive metastatic
4
lapatinib combination
4
obtains volumetric
4
capecitabine lapatinib
4
nervous system
4
systemic treatments
4
activity systemic
4
limiting activity
4

Similar Publications